In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Pharmaceuticals International GmbH

Division of Takeda Pharmaceutical Co. Ltd.
www.nycomed.com

Latest From Takeda Pharmaceuticals International GmbH

Get The Most Out Of Your Marketing Research

Esin Izat, a pharmaceutical marketing research expert, talks to In Vivo about how smaller companies can better utilize pre-launch marketing research and how approaches are changing to reflect new customer profiles and advances in technology.

Business Strategies Market Access

Grifols Wins Early FDA OK For SCIg Xembify, Setting Stage For Margin Growth

Analysts said Grifols is poised for profit margin growth after the US FDA approved its first 20% subcutaneous immunoglobulin, Xembify, for treating primary immunodeficiencies.

Commercial Companies

BIO Notebook Day 3: ARM Launches Foundation To Educate Public About Gene And Cell Therapies

Alliance for Regenerative Medicine initiative seeks to explain gene and cell therapy to the general public. Also, EY's Giovannetti says strategic decisions, not tax reform, should drive deal-making; FDA's Woodcock touts benefits of new drug review office overhaul; and Siga Technologies eyes priority review voucher upon approval of Tpoxx for smallpox.

Regenerative Medicine Deals

BIO Notebook Day 3: ARM Launches Foundation To Educate Public About Gene And Cell Therapies

Alliance for Regenerative Medicine initiative seeks to explain gene and cell therapy to the general public. Also, EY's Giovannetti says strategic decisions, not tax reform, should drive deal-making; FDA's Woodcock touts benefits of new drug review office overhaul; and Siga Technologies eyes priority review voucher upon approval of Tpoxx for smallpox.

Regenerative Medicine Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register